Lantern Pharma (NASDAQ: LTRN) reported Q2 EPS of ($0.21), $0.05 better than the analyst estimate of ($0.26). Revenue for the quarter came in at $0 , versus $0 reported last year.

For earnings history and earnings-related data on Lantern Pharma (LTRN) click here.